drugset / Trial / NCT00766337
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
Timeline
- Start
- 2008-12
- Primary completion
- 2009-11
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 440 ug | Other |
| Subject | Sirolimus | Small molecule | 1320 ug | Other |
| Comparator | Ranibizumab | Monoclonal antibody | 500 ug | Intravitreal |